Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28419176 | 0.98 | PAOX (0.61) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL15685088 | 0.93 | EPHX1 (0.52) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL17373962 | 0.89 | PAOX (0.62) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL14198101 | 0.89 | EPHX1 (0.68) | EPHX1EPHX2PRMT1MEN1KMT2A | |
| SCHEMBL17379928 | 0.89 | PAOX (0.62) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL17740004 | 0.87 | EPHX1 (0.75) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL21667346 | 0.87 | EPHX1 (0.69) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL7215969 | 0.86 | PAOX (0.67) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL7209810 | 0.86 | PAOX (0.67) | PAOXEPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL12353013 | 0.86 | PAOX (0.67) | PAOXEPHX1EPHX2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3173408-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | Taisho Pharmaceutical Co., Ltd. (JP) | 2017-05-31 | — | — | EP | disclosed |
| EP-1275723-B1 | Recombinant D-hydantoin hydrolases and N-carbamyl-D-amino acid hydrolases, and DNA encoding them; uses thereof for producing D-amino acids | AJINOMOTO KK (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | PAOX 1434/4885EPHX1 1843/4885EPHX2 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.